| Outcome Measures: |
Primary: Number of adverse events (AEs), Number of events, From investigational medicinal product (IMP) administration at day 1 (Visit 2) and up to 22 days post IMP administration (Visit 3) | Secondary: Number of hypoglycaemic episodes, Number of episodes, 0 to 24 hours after IMP administration|AUCNNC0471-0119,0-30 min/AUCNNC0471-0119,0-t: Ratio of the area under the serum NNC0471-0119 concentration-time curve from 0-30 min and 0-t, where t is the last observed time point with insulin concentration above lower limit of quantification (LLOQ)., % (Percent), 0 to 12 hours after IMP administration|AUCNNC0471-0119,2h-t/AUCNNC0471-0119,0-t: Ratio of the area under the serum NNC0471-0119 concentration-time curve from 2 hours to t and 0 to t, where t is the last observed time point with insulin concentration above LLOQ., 0 to 12 hours after IMP administration|AUCNNC0471-0119, 0-t: Area under the serum NNC0471-0119 concentration-time curve from 0 to t, where t is the last observed time point with insulin concentration above LLOQ., h\*pmol/L, 0 to 12 hours after IMP administration|Cmax,NNC0471-0119: Maximum observed serum NNC0471- 0119 concentration, pmol/L, 0 to 12 hours after IMP administration|tmax,NNC0471-0119: Time to maximum observed serum NNC0471-0119 concentration, Minutes, 0 to 12 hours after IMP administration|t½, NNC0471-0119: Terminal half-life for NNC0471-0119, Minutes, 0 to 12 hours after IMP administration
|
